NeoStem Inc Stock Nyse
Equities
NBS
US6406503051
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
|
06-13 | Lisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX Trial | CI |
05-20 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 28.83M 39.43M |
---|---|---|---|---|---|
Net income 2024 * | -25M -34.19M | Net income 2025 * | -30M -41.03M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-1.13
x | P/E ratio 2025 * |
-1.29
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 81.21% |
Latest transcript on NeoStem Inc
1st Jan change | Capi. | |
---|---|---|
+38.65% | 39.1B | |
-8.62% | 38.76B | |
+26.95% | 31.24B | |
+10.74% | 25.9B | |
-13.50% | 25.8B | |
+44.87% | 14.06B | |
+34.36% | 13.12B | |
-7.14% | 11.32B | |
-12.61% | 10.68B |
- Stock Market
- Equities
- LSTA Stock
- NBS Stock